In a landmark development for dengue prevention, the Drug Controller General of India (DCGI) has granted market authorization to Takeda Biopharmaceuticals India's QDENGA (Dengue Tetravalent Vaccine [Live, Attenuated]), making it the first dengue vaccine approved in India. The vaccine is approved for the prevention of dengue in individuals 4 to 60 years of age and can be administered regardless of prior dengue infection, eliminating the need for pre-vaccination screening.
B.Pharm OR Bachelors degree in Engineering or Technology or Medicine. Development of Point-of-Care Mycotoxin Detection Methods in Food Matrices. CSIR-National Chemical Laboratory
MSc / MS / MPharm or equivalent degree in Organic Chemistry / General Chemistry / Medicinal Chemistry / Biochemistry etc. PhD Program between BITS Pilani, KK Birla Goa Campus, and IISER Tirupati,
Master Degree in Pharmacy / Forensic Pharmacy with specialization in Pharmacology or concerned/allied/relevant discipline with a very good academic record throughout. two publications in renowned journals of repute UGC -care listed journal/ Web of Science /SCOPUS Indexed journals
Public Health and Allied Subjects, Public Health, Epidemiology, Biostatistics, AI and Digital Health, Social and Behavioral Sciences, etc. Biotechnology, Biochemistry, Microbiology, Life Sciences etc.
Phenome India-CSIR health cohort knowledge base. Institute of Microbial Technology invites Masters / Integrated Masters in Natural or Pharmaceutical Sciences/ MVSc/ Animal Sciences. Or Doctoral Degree
M.Sc/ M.Tech, Biotechnology, Life Sciences or other related field with experience in enzymology/molecular biology techniques. GATE/NET qualification with experience in molecular biology, enzyme kinetics and/or genome engineering will be preferred.
Ph.D. with first class or equivalent grade in the preceding degree in the appropriate branch with very good academic record throughout and at least 8 years of Teaching/ Research/ Industrial experience